Hypoglycemia, diabetes, and cardiovascular disease
- PMID: 22650225
- PMCID: PMC3361183
- DOI: 10.1089/dia.2012.0031
Hypoglycemia, diabetes, and cardiovascular disease
Abstract
Cardiovascular disease (CVD) remains the leading cause of death in people with diabetes, and the risk of CVD for adults with diabetes is at least two to four times the risk in adults without diabetes. Complications of diabetes, including not only CVD but also microvascular diseases such as retinopathy and nephropathy, are a major health and financial burden. Diabetes is a disease of glucose intolerance, and so much of the research on complications has focused on the role of hyperglycemia. Clinical trials have clearly demonstrated the role of hyperglycemia in microvascular complications of diabetes, but there appears to be less evidence for as strong of a relationship between hyperglycemia and CVD in people with diabetes. Hypoglycemia has become a more pressing health concern as intensive glycemic control has become the standard of care in diabetes. Clinical trials of intensive glucose lowering in both type 1 and type 2 diabetes populations has resulted in significantly increased hypoglycemia, with no decrease in CVD during the trial period, although several studies have shown a reduction in CVD with extended follow-up. There is evidence that hypoglycemia may adversely affect cardiovascular risk in patients with diabetes, and this is one potential explanation for the lack of CVD prevention in trials of intensive glycemic control. Hypoglycemia causes a cascade of physiologic effects and may induce oxidative stress and cardiac arrhythmias, contribute to sudden cardiac death, and cause ischemic cerebral damage, presenting several potential mechanisms through which acute and chronic episodes of hypoglycemia may increase CVD risk. In this review, we examine the risk factors and prevalence of hypoglycemia in diabetes, review the evidence for an association of both acute and chronic hypoglycemia with CVD in adults with diabetes, and discuss potential mechanisms through which hypoglycemia may adversely affect cardiovascular risk.
Figures


Similar articles
-
Hypoglycemia, but not glucose variability, relates to vascular function in children with type 1 diabetes.Diabetes Technol Ther. 2012 Jun;14(6):457-62. doi: 10.1089/dia.2011.0229. Epub 2012 Feb 7. Diabetes Technol Ther. 2012. PMID: 22313018 Free PMC article.
-
Do data in the literature indicate that glycaemic variability is a clinical problem? Glycaemic variability and vascular complications of diabetes.Diabetes Obes Metab. 2013 Sep;15 Suppl 2:3-8. doi: 10.1111/dom.12140. Diabetes Obes Metab. 2013. PMID: 24034513 Review.
-
The science of hypoglycemia in patients with diabetes.Curr Diabetes Rev. 2013 May;9(3):195-208. doi: 10.2174/15733998113099990059. Curr Diabetes Rev. 2013. PMID: 23506375 Review.
-
Impact of glycemic treatment choices on cardiovascular complications in type 2 diabetes.Cardiol Rev. 2009 Jul-Aug;17(4):165-75. doi: 10.1097/CRD.0b013e3181a7b34c. Cardiol Rev. 2009. PMID: 19525678 Review.
-
Cardiovascular disease risk in young people with type 1 diabetes.J Cardiovasc Transl Res. 2012 Aug;5(4):446-62. doi: 10.1007/s12265-012-9363-x. Epub 2012 Apr 12. J Cardiovasc Transl Res. 2012. PMID: 22528676 Review.
Cited by
-
Clinical outcomes in high-hypoglycaemia-risk patients with type 2 diabetes switching to insulin glargine 300 U/mL versus a first-generation basal insulin analogue in the United States : Results from the DELIVER High Risk real-world study.Endocrinol Diabetes Metab. 2022 Jan;5(1):e00306. doi: 10.1002/edm2.306. Epub 2021 Nov 22. Endocrinol Diabetes Metab. 2022. PMID: 34807513 Free PMC article.
-
Use of IDegLira to Intensify, Simplify, and Increase Appropriateness of Type 2 Diabetes Therapy: A Real-Life Experience.Diabetes Ther. 2024 Jan;15(1):145-154. doi: 10.1007/s13300-023-01489-z. Epub 2023 Oct 26. Diabetes Ther. 2024. PMID: 37883002 Free PMC article.
-
Glycated albumin and its variability as an indicator of cardiovascular autonomic neuropathy development in type 2 diabetic patients.Cardiovasc Diabetol. 2017 Oct 10;16(1):127. doi: 10.1186/s12933-017-0619-2. Cardiovasc Diabetol. 2017. PMID: 29017498 Free PMC article.
-
Rate-of-Change Dependence of the Performance of Two CGM Systems During Induced Glucose Swings.J Diabetes Sci Technol. 2015 Jul;9(4):801-7. doi: 10.1177/1932296815578716. Epub 2015 Apr 7. J Diabetes Sci Technol. 2015. PMID: 25852074 Free PMC article.
-
Relation between anti-atherosclerotic effects of IRAK4 and modulation of vascular smooth muscle cell phenotype in diabetic rats.Am J Transl Res. 2016 Feb 15;8(2):899-910. eCollection 2016. Am J Transl Res. 2016. PMID: 27158377 Free PMC article.
References
-
- Laing SP. Swerdlow AJ. Slater SD. Burden AC. Morris A. Waugh NR. Gatling W. Bingley PJ. Patterson CC. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia. 2003;46:760–765. - PubMed
-
- Soedamah-Muthu SS. Fuller JH. Mulnier HE. Raleigh VS. Lawrenson RA. Colhoun HM. High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the general practice research database. Diabetes Care. 2006;29:798–804. - PubMed
-
- Lloyd CE. Kuller LH. Ellis D. Becker DJ. Wing RR. Orchard TJ Coronary artery disease in IDDM. Gender differences in risk factors but not risk. Arterioscler Thromb Vasc Biol. 1996;16:720–726. - PubMed
-
- White NH. Sun W. Cleary PA. Danis RP. Davis MD. Hainsworth DP. Hubbard LD. Lachin JM. Nathan DM. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch Ophthalmol. 2008;126:1707–1715. - PMC - PubMed
-
- Nathan DM. Cleary PA. Backlund JY. Genuth SM. Lachin JM. Orchard TJ. Raskin P. Zinman B Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–2653. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical